June 7, 2012Open Access

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Vismodegib is associated with tumor responses in patients with locally advanced or metastatic basal-cell carcinoma. (Funded by Genentech; Erivance BCC ClinicalTrials.gov number, NCT00833417.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Aleksandar Sekulić

Michael R. Migden

Anthony E. Oro

Journals

New England Journal of Medicine

Actions

Institutions

Stanford University

Johns Hopkins University

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study